Close Menu

NEW YORK – Uppsala, Sweden-based proteomics firm Olink on Thursday priced its initial public offering of 17,647,058 common shares at $20 per share, for anticipated gross proceeds of $264.7 million before underwriting discounts, commissions, and other expenses.

The IPO includes 4,411,764 shares offered by the selling shareholders. Shares will be offered in the form of American depositary shares and are expected to begin trading on the Nasdaq Global Market under the symbol OLK on March 25, 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.